Formulation of inhalable lipid-based salbutamol sulfate microparticles by spray drying technique
Tóm tắt
The aim of this work was to develop dry powder inhaler (DPI) formulations of salbutamol sulfate (SS) by the aid of solid lipid microparticles (SLmPs), composed of biocompatible phospholipids or cholesterol. The SLmPs were prepared by using two different solvent systems (ethanol and water-ethanol) and lipid carriers (dipalmitoylphosphatidylcholine (DPPC) and cholesterol) with/without L-leucine in the spray drying process. The spray-dried microparticles were physically-mixed with coarse lactose monohydrate in order to make our final DPI formulations and were investigated in terms of physical characteristics as well as in vitro drug release profile and aerosolization behavior. We observed significant differences in the sizes, morphologies, and in vitro pulmonary depositions between the formulations. In particular, the SS-containing SLmPs prepared with water-ethanol (30:70 v/v) solution of DPPC and L-leucine which had then been blended with coarse lactose (1:9 w/w) exhibited the highest emitted dose (87.9%) and fine particle fraction (42.7%) among the formulations. In vitro drug release study indicated that despite of having a significant initial burst release for both cholesterol and DPPC-based microparticles, the remained drug released more slowly than the pure drug. This study demonstrated the potential of using lipid carriers as well as L-leucine in DPI formulations of SS to improve its aerosolization behavior and retard the release profile of the drug.
Tài liệu tham khảo
Courrier H, Butz N, Vandamme TF: Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002, 19: no. 4-no. 5.
Groneberg D, Witt C, Wagner U, Chung K, Fischer A: Fundamentals of pulmonary drug delivery. Resp Med. 2003, 97: 382-387. 10.1053/rmed.2002.1457.
Labiris N, Dolovich M: Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Brit J Clin Pharmacol. 2003, 56: 588-599. 10.1046/j.1365-2125.2003.01892.x.
Zeng XM, Martin GP, Marriott C: The controlled delivery of drugs to the lung. Int J Pharm. 1995, 124: 149-164. 10.1016/0378-5173(95)00104-Q.
Hardy JG, Chadwick TS: Sustained release drug delivery to the lungs. Clin Pharmacokin. 2000, 39: 1-4.
Cook RO, Pannu RK, Kellaway IW: Novel sustained release microspheres for pulmonary drug delivery. J Control Rel. 2005, 104: 79-90. 10.1016/j.jconrel.2005.01.003.
Schreier H, Gonzalez-Rothi RJ, Stecenko AA: Pulmonary delivery of liposomes. J Control Rel. 1993, 24: 209-223. 10.1016/0168-3659(93)90180-D.
Lu D, Hickey AJ: Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech. 2005, 6: E641-E648. 10.1208/pt060480.
Abra R, Mihalko PJ, Schreier H: The effect of lipid composition upon the encapsulation and in vitro leakage of metaproterenol sulfate from 0.2 μm diameter, extruded, multilamellar liposomes. J Control Rel. 1990, 14: 71-78. 10.1016/0168-3659(90)90062-X.
Parthasarathy R, Gilbert B, Mehta K: Aerosol delivery of liposomal all-trans-retinoic acid to the lungs. Cancer Chemother Pharmacol. 1999, 43: 277-283. 10.1007/s002800050895.
Pilcer G, Amighi K: Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010, 392: 1-19. 10.1016/j.ijpharm.2010.03.017.
Taylor KM, Fan SJ: Liposomes for drug delivery to the respiratory tract. Drug Dev Ind Pharm. 1993, 19: 123-142. 10.3109/03639049309038764.
Kellaway IW, Farr SJ: Liposomes as drug delivery systems to the lung. Adv Drug Deliv Rev. 1990, 5: 149-161. 10.1016/0169-409X(90)90012-H.
Niven RW, Schreier H: Nebulization of liposomes. I. Effects of lipid composition. Pharm Res. 1990, 7: 1127-1133. 10.1023/A:1015924124180.
Desai TR, Hancock RE, Finlay WH: Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur J Pharm Sci. 2003, 20: 459-467. 10.1016/j.ejps.2003.09.008.
Jaspart S, Bertholet P, Piel G, Dogné J-M, Delattre L, Evrard B: Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm. 2007, 65: 47-56. 10.1016/j.ejpb.2006.07.006.
Sebti T, Amighi K: Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur J of Pharm Biopharm. 2006, 63: 51-58. 10.1016/j.ejpb.2005.11.003.
Müller RH, Mäder K, Gohla S: Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm. 2000, 50: 161-177. 10.1016/S0939-6411(00)00087-4.
Trotta M, Cavalli R, Carlotti M, Battaglia L, Debernardi F: Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion–diffusion technique. Int J Pharm. 2005, 288: 281-288. 10.1016/j.ijpharm.2004.10.014.
Pilcer G, Sebti T, Amighi K: Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res. 2006, 23: 931-940. 10.1007/s11095-006-9789-4.
Masters K: Spray drying handbook. 1991, New York: Longman, 5
Steckel H, Brandes HG: A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm. 2004, 278: 187-195. 10.1016/j.ijpharm.2004.03.010.
Chow AH, Tong HH, Chattopadhyay P, Shekunov BY: Particle engineering for pulmonary drug delivery. Pharm Res. 2007, 24: 411-437. 10.1007/s11095-006-9174-3.
Son Y-J, McConville JT: Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm. 2008, 34: 948-959. 10.1080/03639040802235902.
Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, Evrard B: Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech. 2004, 5: 17-23. 10.1208/pt050227.
Nassimi M, Schleh C, Lauenstein H, Hussein R, Hoymann H, Koch W, Pohlmann G, Krug N, Sewald K, Rittinghausen S: A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm. 2010, 75: 107-116. 10.1016/j.ejpb.2010.02.014.
Smolensky M, D’alonzo G, Kunkel G, Barnes P: Day-night patterns in bronchial patency and dyspnea: basis for once-daily and unequally divided twice-daily theophylline dosing schedules. Chronobiol Int. 1987, 4: 303-317. 10.3109/07420528709083521.
Chew NY, Shekunov BY, Tong HH, Chow AH, Savage C, Wu J, Chan HK: Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005, 94: 2289-2300. 10.1002/jps.20426.
Salama RO, Traini D, Chan H-K, Young PM: Preparation and characterisation of controlled release co-spray dried drug–polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008, 70: 145-152. 10.1016/j.ejpb.2008.04.009.
Al-Asheh S, Jumah R, Banat F, Hammad S: The use of experimental factorial design for analysing the effect of spray dryer operating variables on the production of tomato powder. Food Bioprod Process. 2003, 81: 81-88. 10.1205/096030803322088215.
Ståhl K, Claesson M, Lilliehorn P, Lindén H, Bäckström K: The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm. 2002, 233: 227-237. 10.1016/S0378-5173(01)00945-0.
Vehring R: Pharmaceutical particle engineering via spray drying. Pharm Res. 2008, 25: 999-1022. 10.1007/s11095-007-9475-1.
Lechuga‒Ballesteros D, Charan C, Stults CL, Stevenson CL, Miller DP, Vehring R, Tep V, Kuo MC: Trileucine improves aerosol performance and stability of spray‒dried powders for inhalation. J Pharm Sci. 2008, 97: 287-302. 10.1002/jps.21078.
Srichana T, Brain A, Marriott C, Martin GP: A study of drug-carrier interactions in dry powder inhaler formulations using the Andersen cascade impactor, X-ray microanalysis and time of flight aerosol beam spectrometry (TOFABS). Chem Pharm Bull. 2000, 48: 167-174. 10.1248/cpb.48.167.
Scalia S, Salama R, Young P, Traini D: Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. J Microencap. 2012, 29: 225-233. 10.3109/02652048.2011.646326.
Yu J, Chien YW: Pulmonary drug delivery: physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst. 1997, 14: 395-453.
Bosquillon C, Lombry C, Preat V, Vanbever R: Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci. 2001, 90: 2032-2041. 10.1002/jps.1154.
Zeng XM, Martin GP, Marriott C: Particulate Interactions in Dry Powder Formulation for Inhalation. 2000, London: Taylor & Francis